- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01588288
Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter (Galectins)
Diagnosis Interest of Galectin 3 Dosage in Nodular and Multinodular Goiter Pretreatment
Study Overview
Detailed Description
Endogenous cell-surface galectins have recently gained interest as antigenic determinants of varied tumor tissue. They are also used as potential targets for antitumor therapy by coupling cytotoxic molecules or radioisotopes either with carbohydrate residues, or with antibodies antigalectines.
In addition, the plasma level dosage of galectin 3 seems possible and provides a diagnostic help in thyroid lesions and in monitoring squamous cell head and neck.
In a study on thyroid tumors, the sensitivity [Se] and specificity [Sp] of the plasma level was poor (just over 70%), but this study was conducted with a low and heterogeneous recruitment (70 patients). The inclusion of a greater number of patients with a better selection would better inform us about qualities of these diagnostic assays.
An additional argument would be the dosage of galectins in the water rinse of the needle aspiration biopsy. This study has never been made so far and there is no evidence to predict its sensitivity and specificity. The advantage is that galectin will not be "diluted" as would be the case in an assay done in the blood. Moreover, it would select candidates for dosage nodules, ie those whose size would impose, if it was a cancer, to resort to surgical treatment more extensive than originally planned. Indeed, compared to preoperative already existing metering "interesting" dosage would diagnose:
- with a good reliability (Se and Sp > 80%)
- a cancer requiring additional treatment (i.e. surgical revision to achieve a total thyroidectomy, accompanied by lymph node dissection) resulting in a higher risk of morbidity if reoperation.
The investigators therefore believe that preoperative galectin 3 dosage in plasma or in the puncture water rinse could have strong arguments pointing to a neoplastic to a full initial gesture in a single surgical step, a gesture much less risky and expensive.
In this study, patients benefit from routine monitoring of thyroid nodules according to current recommendations. For surgical patients only, the information about the intervention will be collected to know the final histological diagnosis.
Galectin 3 will be measured preoperatively in :
- plasma
- water rinse of FNA.
The diagnostic characteristics of the assays, sensitivity and specificity will be established relative to the reference method which is the histological analysis of the specimen (report) asserting the existence of a vesicular lineage tumor, benign (adenoma) or malignant (papillary or follicular).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rouen, France, 76000
- Centre Henri Becquerel
-
Rouen, France, 76000
- CHRouen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women
- 18 years old or more
- Patient with one or more thyroid nodules with the following definition :
A nodule is a circumscribed intraparenchymal expansive development. This is thus a structure that appears on two cuts perpendicular ovoid. a nodule is visible on ultrasound by their mass effect (contour deformation), its ultrasound contrast relative to adjacent parenchyma or by repression of vascular structures at its periphery (halo and cantilever)
- Indication for a cytopuncture, in the opinion of the investigator
- Definitive postoperative histological analysis confirming a benign or malignant tumor of vesicular lineage cells.
- Patient affiliated to the french public welfare system
- Patient who signed an informed consent
Exclusion Criteria:
- Simple goiter
- Thyroid dysfunction
- Hashimoto's thyroiditis
- Basedow's disease
- No surgery at the end of the study
- After definitive postoperative histological analysis : lymphoma, medullary thyroid carcinoma, anaplastic thyroid cancer, or focal Hashimoto's thyroiditis
- Pregnancy
- Major under guardianship,
- Person deprived from him administrative and judicial liberty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Galectin 3 dosage
Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
|
Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity (Se) and specificity (Sp) of plasmatic galectin 3 dosage in preoperative
Time Frame: 1 day
|
Se and Sp of plasmatic galectin 3 dosage will be established relative to the reference method which is the histological analysis of the specimen (report) asserting the existence of a vesicular lineage tumor, benign (adenoma) or malignant (papillary or follicular). The threshold giving the best compromise for the values of Se and Sp will be searched graphically. Then the area under the curve and its confidence interval at 95% will be calculated and will be tested against the value 0.5, that is to say an area where the assay has no diagnostic value. |
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity (Se) and specificity (Sp) of preoperative galectin 3 dosage in the water rinse of the needle aspiration biopsy
Time Frame: Once in preoperative
|
Se and Sp of galectin 3 dosage in the water rinse of the needle aspiration biopsy will be established relative to the reference method which is the histological analysis of the specimen (report) asserting the existence of a vesicular lineage tumor, benign (adenoma) or malignant (papillary or follicular). The threshold giving the best compromise for the values of Se and Sp will be searched graphically. Then the area under the curve and its confidence interval at 95% will be calculated and will be tested against the value 0.5, that is to say an area where the assay has no diagnostic value. |
Once in preoperative
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne CAILLEUX, MD, Rouen university hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011/042/HP
- 2011-A00569-32 (Registry Identifier: RCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Goiter, Nodular
-
Steen BonnemaCompleted
-
Steen BonnemaCompleted
-
Odense University HospitalCompleted
-
Jan CalissendorffRecruiting
-
Central South UniversityUnknown
-
National Taiwan University HospitalCompleted
-
Bezmialem Vakif UniversityCompleted
-
Castilla-León Health ServiceCompleted
Clinical Trials on Galectin 3 dosage
-
Recep Tayyip Erdogan University Training and Research...CompletedAnkylosing Spondylitis
-
Necmettin Erbakan UniversityCompletedPlacenta Accreta, Third TrimesterTurkey
-
University of MessinaCompleted
-
Cliniques universitaires Saint-Luc- Université...Terminated
-
Assiut UniversityCompleted
-
Assiut UniversityUnknown
-
Almirall, S.A.Completed
-
Trinomab Biotech Co., Ltd.TIGERMED AUSTRALIA PTY LIMITEDCompletedHealthy Adult SubjectsAustralia
-
Assiut UniversityNot yet recruitingGalectin-3 and Pemphigus